Old API Wind-down Ltd - Ordinary Shares ARLZQ

Institutional buyer or Fund @ $5.50 US

[Bigboyone]

Frustrating Stock, no small shareholder is selling here, especially with the possibility of good news right around the corner.
Its so abvious, Aralez stock is being placed somewhere for $5.50 a share.
600k worth of shares traded by 12:00 pm. EST. Do the Math how many shares traded last two weeks, who know how much is really held by insiders.
Could they make it look more obvious? We need to break and hold @ $5.70 or better in my calculation, for resistance, to hit mid $6.'s
I use 10-20-50 & 200 Day Moving Averages. I like to see the 200 day line crossed or getting close to it.
I also use, Candlesticks, Stochastics, Momentum and a few others. 

I will be selling a small % of my shares a day or 2 after, (hopefully) Yosprala, FDA passed.
I think the way the stock trades it doesnt go straight up. The funds involved also need to "Churn" accounts. Just my 2 cents...GLTA..

[GoldenDilemma]

The chart is simply overbought.  The party can't go on forever. Play both sides long/short. Pull back necessary for the next leg up! 

[biggerr]

somebody is kicking our ARZ, can't wait for the early FDA approval after the Labor Day, ha

[GoldenDilemma]

Both charts overbought. Not sure why a pull back is surprising. 

[Bigboyone]

GoldenDI - I disagree, you are basing the pullback on one parameter?Being overbought? I have seen overbought stocks go on for two weeks or more.  Explain to me the Volume? The Outstanding shares vs. Common Shares?  750k to Mil + shares Every day, traded in  the last 2-3 weeks? Even with "Crossing" and Double Counts" in the total, it doesnt compute. There are 38 Mil in

[kuatolives]

Just a guess, but there are a bunch of traders out there that play the PDUFA dates with stop losses in case the thing goes south. I think everyone who wanted to invest did so, and I think a bunch of traders piled on with some stop losses, hence the big swing in the last couple of days. I shared the sentiment that a bid of a purge probably isn't a bad thing right now leading up to the

[select1011]

This post has been removed in accordance with Community Policy

[GoldenDilemma]

Still sure about this? ;)

[Bigboyone]

I hope I am wrong,...I would be the firs to admit it.. I have been with this situation too long (my own fault, I believed the hype) This stoc k does not follow technicals or fundamentals (Overbought or sold). To some degree it wwill follow moving averages. This Stock does follow market and sector pressure and is manipulated by the Instituition (s) holding this stock. Thats a fact. I cannot prove

[Floridas2000]

I understand where you're coming from.  All the small investors are waiting for the Yosprala approval and the only person selling now are traders or people who need money for personal reasons.  This can be institutions getting ready for what's coming up and controlling the rise. The good things though: - the stock is going up so the expectation is approval of Yosprala and that&

[GoldenDilemma]

Expecting close to 100% from YTD lows on speculation for drug approval? Get your head out of the clouds.  On the other hand, from current price levels and if the drug gets approved, I would not be surprised to see us retest last years highs. It was incredibly irrational that we did 100%+ last year on an M&A announcement, yet, it happened. If Yosprala manages to get approved after how

[kuatolives]

What are we looking at for valutions that would be considered overbought (after approval, assuming, of course)? Could we hit $10 (ARLZ) in the 2-3 days following a positive annoucement? I don't want to make the same mistake I made with TRX and hold too long if the market decides to overbuy on news, only to take itself down 20% waiting for earnings to catch up. I don't mind investing again,

[GoldenDilemma]

@kuat, Let's see what happens post news. Basic technical analysis will give us the best indication of where/when we should exit. Even in hindsite, if you look to what happened last year before Hillary and then the s h i t show that ensued, we did not manage to hold the $12 zone on good volume (POZN) and the chart was forming a bearish double top. That was indicative of shorts piling in and

[Bigboyone]

Golden- I joined this forum as I enjoyed reading the feedback and posts for Tribute. They where informative, bright and enlightening. I agree with many of your points, but i beg to diagree on others, if you feel I am trying my own agenda, thats totoaly wrong. I have made some mistakes here and have made the mistake of falling in love (like ) with a story. I know for some of the readers,(not all

[Bigboyone]

Hmm, makes me feel a  bit vindicated with all my pointing out "front running " by insiders and Institutional players here ... Now the  News is out on the new drug purchase from Merck and we are a few pennies down after the run-up of early today. I still feel the 1.3 mil shares traded yesterday, had nothing to do with being "Oversold", this stock doesn't ot follow

[kuatolives]

I just assume everyone's a crook or stupid; makes planning life easier. Wish they'd released sales figures for this one. I assume they are in the 10-15M range as that would make sense for both Merck to cut the drug loose (not worth their time) and for ARLZ to pick it up as it now gives their sales reps 3 cardio drugs to push in the US when they hit the road (Yosprala (assuming approval

[Floridas2000]

Notes: In May 2014, Merck announced that the FDA approved Zontivity for the reduction of thrombotic  cardiovascular events in patients with a history of myocardial infarction or with peripheral arterial disease. The U.S. prescribing information for Zontivity includes a boxed warning regarding bleeding risk. In January 2015, Zontivity was approved by the EC for coadministration with

[kuatolives]

Like Adams said back when ARLZ was formed, it's easier to run/sell a company when it has a platform.  

[Floridas2000]

Target population    [A0007] What kinds of patients are targeted by vorapaxar’s indication?    Vorapaxar is indicated for the reduction of atherothrombotic events in adult post-MI patients  without a history of stroke or TIA, without a history of intracranial haemorrhage, and without any  active pathological bleeding or hypersensitivity to the active